PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ptct · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for PTC Therapeutics, Inc. (PTCT) measures how much investors pay for each dollar of the company's trailing earnings. PTCT's current PE ratio of N/A is calculated by dividing its stock price of $70.87 by its TTM earnings per share of -$2.26.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
PTC Therapeutics, Inc.You PTCT | $5.9B | N/A | — | -$2.26 |
 Arcellx, Inc. ACLX | $6.7B | N/A | — | -$4.07 |
 Alkermes plc ALKS | $7.1B | 19.07x | -29.3% | $1.47 |
 Arrowhead Pharmaceuticals, Inc. ARWR | $10.4B | N/A | — | -$0.01 |
 Crinetics Pharmaceuticals, Inc. CRNX | $3.5B | N/A | — | -$4.95 |
 Krystal Biotech, Inc. KRYS | $8.9B | 34.84x | +29.3% | $7.08 |
 Metsera, Inc. MTSR | $7.4B | N/A | — | -$2.03 |
Industry Average 2 peers with valid PE | — | 26.95x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 8.85x | $8.58 | — | |
2024-12-31 FY2024 | — | $-4.73 | — | |
2023-12-31 FY2023 | — | $-8.37 | — | |
2022-12-31 FY2022 | — | $-7.79 | — | |
2021-12-31 FY2021 | — | $-7.43 | — | |
2020-12-31 FY2020 | — | $-6.64 | — | |
2019-12-31 FY2019 | — | $-4.27 | — | |
2018-12-31 FY2018 | — | $-2.75 | — | |
2017-12-31 FY2017 | — | $-2.02 | — | |
2016-12-31 FY2016 | — | $-4.17 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for PTC Therapeutics, Inc. (PTCT) measures how much investors pay for each dollar of the company's trailing earnings. PTCT's current PE ratio of N/A is calculated by dividing its stock price of $70.87 by its TTM earnings per share of -$2.26.
Frequently asked questions
PTCT pe ratio · 6 questionsPTCT's current PE ratio is N/A as of 2026-06-08, based on a stock price of $70.87 and TTM EPS of -$2.26. Data sourced from Financial Modeling Prep via PTCT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · PTC Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08